CLOSED
NIFTY 5022,453.30+0.98%SENSEX74,235.62+1.24%BANK NIFTY48,892.15+1.45%NIFTY IT35,124.80-0.52%NIFTY MIDCAP52,487.25+0.87%NIFTY 5022,453.30+0.98%SENSEX74,235.62+1.24%BANK NIFTY48,892.15+1.45%NIFTY IT35,124.80-0.52%NIFTY MIDCAP52,487.25+0.87%
Home/Business/Companies/Biocon Launches Biosimilars Bosaya & Auk…

Biocon Launches Biosimilars Bosaya & Aukelso in US

Companies
By ThePip Desk•
Add as a preferred source on Google
A female executive in a suit speaks into a microphone at a conference table, with other executives listening.

Biocon executive speaks at a U.S. launch event for new biosimilar drugs.

Key Highlights

Biocon introduces Bosaya and Aukelso biosimilars in the US for treating bone conditions. Aims to provide affordable treatment options. FDA approved.

Biocon has announced the launch of two new biosimilar medicines, Bosaya and Aukelso, in the United States. These medications are designed to treat serious bone conditions.

The drugs are now available to patients through specialty pharmacies and healthcare providers. The US Food and Drug Administration had previously granted approval for these biosimilars.

This launch marks an expansion of Biocon’s portfolio and is intended to provide more affordable treatment options for patients.

BioconMedicinesUnited StatesUS Food and Drug Administration